This opportunity is no longer accepting applications.
grant PAR-24-223

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

This grant opportunity supports the early development of new small-molecule and biologic drugs aimed at preventing, slowing, or treating Alzheimer's disease. Funding is available for activities including medicinal chemistry, pharmacokinetics, toxicology studies, animal model efficacy, biomarker development, drug formulation, GMP chemical synthesis, IND-enabling studies, and Phase I clinical tr…

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and beh…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute on Aging
Program: SBIR

Awards & funding

Award Ceiling: $1.5M
Award Amount: $1.5M

Dates

Opportunity Released: June 25, 2024
Open for Submission: June 25, 2024
Submission Deadline: November 5, 2027
Application Window Closes: November 5, 2027

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.